Number needed to immunize to prevent RSV with extended half-life monoclonal antibody.

ABSTRACT:

Background

Respiratory syncytial virus (RSV) is one of the most important respiratory pathogens in young children. Infants <6 months of age and infants and young children with extreme pre-term birth, and cardiac and pulmonary co-morbidities experience the highest incidence of severe RSV disease. There are no licensed vaccines; immunoprophylaxis is recommended for the highest risk children. Extended half-life RSV monoclonal antibodies (EHL-mAbs) are under development intended for immunization of all infants and high-risk children <2 years of age. We modeled the anticipated public health benefits of RSV EHL-mAb immunization using the number needed to immunize (NNI).

Methods

We combined RSV hospitalization, outpatient and outpatient lower respiratory tract infection (LRI) incid

SUBMITTER: Finelli L 

PROVIDER: S-EPMC8684408 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature